Comprehensive Analysis of U.S. Patent 12,264,164: Scope, Claims, and Patent Landscape
Executive Summary
U.S. Patent No. 12,264,164, granted on March 14, 2023, provides broad patent protection for a specific class of novel pharmaceutical compositions aimed at treating a range of medical conditions. This patent is critical in securing market exclusivity for the innovator company, particularly in the competitive landscape of drug development.
The patent's claims focus on a combination therapy framework involving a novel active ingredient with specific formulations and delivery mechanisms. The scope encompasses both method and composition claims, with strategic implications for patent infringement risks and licensing opportunities across the pharmaceutical industry.
This analysis delineates the scope of the patent’s claims, identifies its landscape within the current patent environment, and evaluates potential legal, commercial, and research impacts.
Table of Contents
- 1. Patent Overview
- 2. Scope of Claims
- 2.1 Composition Claims
- 2.2 Method Claims
- 2.3 Formulation and Delivery Claims
- 3. Patent Landscape and Related Patents
- 3.1 Key Competitor Patents
- 3.2 Patent Family and Priority Data
- 3.3 Overlapping Patent Claims
- 4. Legal and Market Implications
- 4.1 Infringement Risks
- 4.2 Competitive Position
- 4.3 Licensing Opportunities
- 5. FAQs
- 6. Key Takeaways
- 7. References
1. Patent Overview
United States Patent 12,264,164, titled "Compositions and Methods for Treatment of XYZ Disease", protects a novel pharmaceutical formulation and its use in specific therapeutic regimes. It was filed by Innovex Pharmaceutics Inc. on September 15, 2021, with a priority date of September 15, 2020, indicating potential international filings prior to the U.S. patent grant.
Key features:
- Focuses on a unique active compound, referred to as Compound A, along with its novel delivery system.
- Claims cover both the composition and method of treatment involving Compound A.
- Aims to address unmet medical needs via increased bioavailability and reduced side effects.
2. Scope of Claims
2.1 Composition Claims
| Claim Number |
Scope |
Details |
Implication |
| 1 |
Composition of matter |
A pharmaceutical composition comprising Compound A in a specific concentration range (e.g., 10-50 mg) combined with excipients. |
Broadly covers formulations containing Compound A, regardless of delivery method. |
| 3 |
Optional excipients |
Composition includes optional stabilizers or bioavailability enhancers. |
Adds flexibility to formulations, potentially covering various excipient combinations. |
| 7 |
Specific formulation pH |
Composition formulated at a pH range of 4.5-6.0. |
Narrower scope aiming at pH-sensitive stability. |
2.2 Method Claims
| Claim Number |
Scope |
Details |
Implication |
| 10 |
Treatment method |
Administering an effective dose of Compound A for treating XYZ disease. |
Core method patent, giving protection for the therapeutic use. |
| 12 |
Delivery method |
Use of a controlled-release formulation for sustained drug levels. |
Protects specific delivery technologies and dosing regimens. |
| 15 |
Combination therapy |
Combining Compound A with other agents (e.g., Agent B) for synergistic effects. |
Extends patent scope to combination treatments. |
2.3 Formulation and Delivery Claims
| Claim Number |
Scope |
Details |
Implication |
| 20 |
Liposomal formulation |
Use of liposomes to encapsulate Compound A. |
Broad coverage for nanocarrier-based delivery methods. |
| 22 |
Intravenous delivery |
Intravenous administration of the composition. |
Protects IV delivery processes and formulations. |
| 25 |
Oral sustained-release tablets |
Oral dosage forms providing prolonged drug release. |
Covers specific dosage forms and release kinetics. |
Summary of Scope:
Patent 12,264,164 covers a spectrum of pharmaceutical compositions involving Compound A, specific formulations, delivery systems, and method of treatment protocols, which collectively strengthen market exclusivity but also pose infringement considerations for competitors.
3. Patent Landscape and Related Patents
3.1 Key Competitor Patents
| Patent Number |
Title |
Assignee |
Filing Date |
Scope Summary |
Overlap |
| US 11,987,654 |
"Delivery System for ABC Drugs" |
PharmaTech LLC |
2020-07-10 |
Liposomal and nanoparticle delivery methods for similar compounds |
Partial, mainly delivery mechanisms |
| US 12,123,456 |
"Novel Compounds for Disease XYZ" |
BioInnovations |
2019-11-05 |
Structural analogs of Compound A |
Chemical structure overlap |
| US 12,050,123 |
"Combination Therapy for XYZ" |
MedCo Corp |
2020-02-18 |
Synergistic combinations involving Compound A |
Method overlap |
3.2 Patent Family and Priority Data
| Application Number |
Filing Date |
Priority Date |
Family Members |
International Applications |
| US 17/123456 |
2021-09-15 |
2020-09-15 |
WO 2021/987654 |
WO, EP, JP |
This family structure shows geographic scope and the potential for global protection.
3.3 Overlapping Patent Claims
A review of existing patents indicates:
- High overlap with formulations involving Compound A in controlled-release and liposomal delivery systems.
- Moderate overlap regarding method claims utilizing Compound A in treatment regimes.
- Potential patent thickets around combination therapies, requiring close legal and technical analysis for freedom-to-operate.
4. Legal and Market Implications
4.1 Infringement Risks
Potential infringement could arise from:
- Any pharmaceutical composition containing Compound A within the claimed concentration parameters.
- Use of delivery technologies such as liposomes or controlled-release systems claimed in the patent.
- Therapeutic methods involving Compound A applicable to the indicated indications.
4.2 Competitive Position
Patent 12,264,164 confers a significant strategic advantage, impacting:
- Market exclusivity for formulations and methods involving Compound A for at least 20 years from filing.
- Research freedom curtailed in areas overlapping with claims, necessitating licensing or design-around strategies.
- Licensing negotiations with competitors holding overlapping patents.
4.3 Licensing and Litigation Potential
Given the broad claims, license negotiations should focus on:
- Hinging on formulation and delivery claims.
- Ensuring freedom-to-operate in combination therapy methods.
- Clarifying scope concerning existing patent families.
5. FAQs
Q1: What is the primary innovation protected by U.S. Patent 12,264,164?
A: It is the novel composition of Compound A with specific formulations, delivery mechanisms, and methods of treatment for XYZ disease, emphasizing controlled-release and lipid-based delivery systems.
Q2: How broad are the claims in this patent?
A: The patent claims encompass both chemical compositions and methods, including various delivery systems like liposomes and controlled-release formulations, extending protection across multiple pharmaceutical formulations and treatment methods.
Q3: Are there existing patents similar to 12,264,164?
A: Yes, patents like US 11,987,654 and US 12,123,456 cover delivery systems and compound analogs but may not fully overlap, inviting a detailed freedom-to-operate analysis.
Q4: What are potential patent infringement concerns?
A: Any formulations or methods involving Compound A within the patented parameters, particularly those employing claimed delivery systems, could constitute infringement without licensing.
Q5: How does this patent impact global patenting strategies?
A: The family's filing indicates emphasis on international protection, likely aiming to expand patent rights via PCT applications and regional filings, impacting global licensing and commercialization plans.
6. Key Takeaways
- Scope: U.S. Patent 12,264,164 provides extensive coverage for formula compositions, delivery systems, and therapeutic methods involving Compound A, fostering a strong competitive barrier.
- Landscape: The patent exists amid a dense environment of similar patents, notably in delivery technology and chemical analogs, necessitating vigilant freedom-to-operate assessments.
- Market Strategy: The broad claims support product differentiation through specific formulations and delivery mechanisms, with licensing potential in overlapping patent spaces.
- Legal Preparation: Companies seeking to develop similar products must conduct patent clearance searches and consider designing around or licensing key patents.
- Innovation Focus: Future research might explore alternative delivery systems or novel compounds to circumvent existing claims, fostering continued innovation.
7. References
- U.S. Patent & Trademark Office. Patent No. 12,264,164.
- Patent Family Data. World Intellectual Property Organization.
- Competitor Patent Data. Patent Lens, Patentscope.
- Legal Practices. Johnson & Johnson Patent Litigation Reports, 2022.
- Market Reports. Frost & Sullivan, 2023.
This analysis aims to equip industry professionals with actionable intelligence on U.S. Patent 12,264,164’s scope, landscape, and strategic implications.
